Want to join the conversation?
As a percent of total revenue, $KORS' total OpEx increased 250 BP to 34.6%. This was below the 440-490 BP of deleverage in the guidance as sales exceeded the company's expectations, and depreciation expense and SG&A were somewhat lower than anticipated. SG&A expenses increased 13% to $345.2MM.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.